United Arab Emirates Ministry of Health and Prevention Approves Biomerica's Fortel® PSA Screening Test to Detect an Early Sign of Prostate Cancer

Core Insights - Biomerica, Inc. has received approval for its Fortel Prostate Specific Antigen (PSA) Screening Test from the United Arab Emirates Ministry of Health and Prevention, marking a significant step in early prostate cancer detection [1][3] Group 1: Product Overview - The Fortel PSA Screening Test is a rapid diagnostic tool that provides results in just 10 minutes using a finger-prick blood sample, enabling early detection of prostate cancer and related conditions [2] - The test measures elevated PSA levels, which are recognized as an early marker of prostate disease, aiming to enhance proactive health management and improve patient outcomes [2] Group 2: Strategic Expansion - The approval of the Fortel PSA test is part of Biomerica's strategy to expand its presence in the Middle East, where prostate cancer is increasingly recognized as a public health concern [3] - Biomerica aims to replicate its success with the EZ Detect Colon Disease At-Home Screening Test in the region, having established partnerships with leading distributors and secured key regulatory approvals [3] Group 3: Performance Validation - The Fortel PSA test has shown impressive performance metrics, with a study reporting 100% sensitivity, 95% specificity, and 97.5% accuracy, aligning with laboratory reference methods [8] - Additional research from Ain Shams University in Egypt validated the test's effectiveness, achieving 97.2% sensitivity, 96.2% specificity, and 96.7% accuracy [8] Group 4: Industry Context - Prostate cancer is the second most common cancer among men globally, with 1.4 million new cases and 375,000 deaths reported in 2020, highlighting the urgency for effective early detection methods [5] - The disease's prevalence and severity vary across different regions, age groups, and ethnicities, indicating a significant public health challenge, particularly in the Middle East [5] Group 5: Future Commitment - Biomerica is committed to expanding access to innovative diagnostic solutions in the Middle East, focusing on providing affordable and accurate tools for early detection and treatment of critical diseases like prostate cancer [6]